Pharma research in ‘late stages’ of 460 rare disease treatments

Posted Atguttridge.co.uk

Around 460 medicines to treat rare diseases are in the late stages of development, and have the potential to change the pharmaceutical processing supply chain.

Many of these are either awaiting clinical trials or – in the US – approval by the Food and Drug Administration, so could arrive on the market soon.

The findings of the report from the Pharmaceutical Research and Manufacturers of America have been broadly welcomed by the industry.

National Organisation for Rare Disorders president Peter Saltonstall explained: "The patient community applauds those individuals and companies choosing the less-travelled research path.

"We are hopeful that many rare disease patients who currently have no treatment will someday benefit from these very important research efforts."

The findings come after a recent report by PricewaterhouseCoopers recommended fundamental changes to the UK pharmaceutical industry, which is currently ill-equipped to meet the sector's emerging and future demands.

The report claimed that there is a lack of infrastructure to produce and distribute the kinds of complex treatments that will soon be required.

Typical Guttridge equipment used in the pharmaceutical industry includes; Feeders – metering screw feeders – weighing systems.

Mar 07, 2011